Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Receivables (2020 - 2026)

GeneDx Holdings has reported Receivables over the past 7 years, most recently at $76.9 million for Q1 2026.

  • Quarterly Receivables rose 67.3% to $76.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $76.9 million through Mar 2026, up 67.3% year-over-year, with the annual reading at $74.4 million for FY2025, 97.64% up from the prior year.
  • Receivables was $76.9 million for Q1 2026 at GeneDx Holdings, up from $74.4 million in the prior quarter.
  • Over five years, Receivables peaked at $76.9 million in Q1 2026 and troughed at $445000.0 in Q4 2023.
  • The 5-year median for Receivables is $38.2 million (2024), against an average of $38.0 million.
  • Year-over-year, Receivables plummeted 98.94% in 2023 and then soared 8355.96% in 2024.
  • A 5-year view of Receivables shows it stood at $2.2 million in 2022, then plummeted by 79.85% to $445000.0 in 2023, then soared by 8355.96% to $37.6 million in 2024, then skyrocketed by 97.64% to $74.4 million in 2025, then rose by 3.44% to $76.9 million in 2026.
  • Per Business Quant, the three most recent readings for WGS's Receivables are $76.9 million (Q1 2026), $74.4 million (Q4 2025), and $60.9 million (Q3 2025).